

Best Foods For your heart trial: dietary intervention to reduce cardiovascular risk in HIV dyslipidaemia

Submission date 08/08/2013	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
Registration date 08/08/2013	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 14/10/2020	Condition category Infections and Infestations	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Background and study aims

Successful treatment for HIV has led to an ageing HIV-positive population with heart disease as the most common cause of death. The underlying cause of the increased risk of heart disease observed in HIV is not understood, and cannot be explained by traditional risk factors. Lifestyle intervention is recommended, with a low-fat diet to promote cholesterol reduction. The addition of functional foods (such as plant stanols and nuts) produces more dramatic reductions in cholesterol. This is based on evidence from the general population. This study will find out if the Ultimate Cholesterol Lowering Plan (UCLP) will have a similar effect in people who have raised cholesterol due to their HIV infection and treatment.

Who can participate?

Adults with HIV infection on stable antiretroviral therapy and raised cholesterol can take part in this study.

What does the study involve?

Participants will be randomly allocated to receive dietary advice on either reducing saturated fat alone, or together with increasing intake of nuts, plant stanols, soya protein, olive oil, beans and oats (components of the UCLP), delivered for 6 months. Results from blood tests, questionnaires and interviews will assess the impact of the UCLP on the risk of heart disease in adults with HIV infection on antiretroviral therapy.

What are the possible benefits and risks of participating?

If this diet can significantly reduce blood cholesterol levels, patients may reduce their risk of a heart attack. Risks to participants are not expected in this study. Potential malabsorption of fat soluble vitamins will be monitored. Participants will be directed to their doctor in the case of any health concerns arising during the study.

Where is the study run from?

The study is run from the Heart of England NHS Foundation Trust (UK), University Hospital Birmingham (UK) and Coventry and Warwickshire Partnership NHS Trust (UK).

When is the study starting and how long is it expected to run for?
The study starts in September 2013 and is expected to run until September 2016.

Who is funding the study?
National Institute for Health research (NIHR) (UK)

Who is the main contact?
Mrs Clare Stradling
clare.stradling@heartofengland.nhs.uk

Contact information

Type(s)
Scientific

Contact name
Mrs Clare Stradling

Contact details
Birmingham Heartlands Hospital
3 Bordesley Green East
Bordesley Green
Birmingham
United Kingdom
B9 5SS
-
clare.stradling@heartofengland.nhs.uk

Additional identifiers

Protocol serial number
14823

Study information

Scientific Title
A randomised controlled pilot study to assess the feasibility of the ultimate cholesterol lowering plan dietary intervention for cardiovascular risk reduction in HIV dyslipidaemia

Acronym
BFF Trial

Study objectives
To test the feasibility and acceptability of the ultimate cholesterol lowering plan (UCLP).

Ethics approval required
Old ethics approval format

Ethics approval(s)

Study design

Randomised; Interventional; Design type: Treatment

Primary study design

Interventional

Study type(s)

Prevention

Health condition(s) or problem(s) studied

Topic: Infection; Subtopic: Infection (all Subtopics); Disease: Infectious diseases and microbiology

Interventions

Dietary intervention:

Diet 1: low saturated fat

Diet 2: low saturated fat, Ultimate Cholesterol Lowering Plan within Mediterranean style diet

The intervention is for 6 months, the follow up is for 12 months.

Intervention Type

Behavioural

Primary outcome(s)

Feasibility and acceptability of trial procedures for recruitment, allocation, retention and the intervention. They will be measured at baseline, 6 and 12 months. Method used to measure these outcomes: recruitment rate, attrition rate, process evaluation questionnaires and qualitative interviews, compliance rate of participation, adherence to dietary intervention using food diaries and 5 question compliance score.

Key secondary outcome(s)

1. Difference in LDL-cholesterol between groups at 6 months
2. Estimates of variability and effect size for waist circumference, arterial stiffness, and other cardiovascular risk factors

Completion date

02/09/2016

Eligibility

Key inclusion criteria

1. Aged 18 years of age with stable HIV infection
 2. On antiretroviral therapy for more than 6 months
 3. Low Density Lipoprotein (LDL)-cholesterol >3mmol/l
 4. Willing to make dietary changes
 5. Able to give informed consent
- Target Gender: Male & Female; Lower Age Limit 18 years

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Total final enrolment

60

Key exclusion criteria

1. Current opportunistic infection or recent weight loss in last 3 months
2. Pregnancy, or planning pregnancy in the next 6 months
3. Diagnosis of familial hyperlipidaemia (LDL-cholesterol >6mmol/l and family history)
4. Secondary causes of hypercholesterolemia
5. Renal or liver disease, diabetes, hypothyroidism (unless treated and on a stable dose of L-thyroxine)
6. Gross xanthoma, as this may predispose to hyper-absorption of plant sterols
7. Blood triglyceride level >10mmol/l, as this constitutes risk of pancreatitis
8. Nut allergy
9. Current use of lipid lowering agents, or any other interfering drug/diet
10. Cannot read and write in English, or inability to understand the printed materials
11. Any unstable psychiatric disorder, including known eating disorders
12. Current participation in a weight loss programme or other dietary intervention

Date of first enrolment

02/09/2013

Date of final enrolment

02/09/2016

Locations**Countries of recruitment**

United Kingdom

England

Study participating centre

Birmingham Heartlands Hospital

Birmingham

United Kingdom

B9 5SS

Sponsor information

Organisation

University of Birmingham (UK)

ROR

<https://ror.org/03angcq70>

Funder(s)

Funder type

Government

Funder Name

NIHR Doctoral Research Fellowship, UK; Grant Codes: NIHR-DRF-2012-05-204

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/03/2021	14/10/2020	Yes	No
Protocol article	protocol	08/02/2016		Yes	No
HRA research summary			28/06/2023	No	No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes